Esperion upgraded to Neutral from Sell at Goldman Sachs
Goldman Sachs analyst Paul Choi upgraded Esperion Therapeutics to Neutral from Sell with an unchanged price target of $50. The analyst views the risk/reward as more balanced at current share levels.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.